0.8 C
London
Friday, November 22, 2024
HomeTagsEisai's

Tag: Eisai's

spot_imgspot_img

Japan – Eisai’s Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial...

Eisai’s Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study

Eisai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis,...

Eisai’s Statement of Commitment for Carbon Neutrality by 2040

Eisai Co., Ltd. announced today that it has pledged to reduce greenhouse gas (GHG) emission which causes global warming, with an aim to achieve...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

spot_img